Merck & Company Inc (MRK)vsPACS Group, Inc. (PACS)
MRK
Merck & Company Inc
$128.58
+0.16%
HEALTHCARE · Cap: $316.14B
PACS
PACS Group, Inc.
$48.44
+3.79%
HEALTHCARE · Cap: $7.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1111% more annual revenue ($65.77B vs $5.43B). MRK leads profitability with a 13.6% profit margin vs 4.5%. PACS appears more attractively valued with a PEG of 1.38. PACS earns a higher WallStSmart Score of 60/100 (C+).
MRK
Hold50
out of 100
Grade: D+
PACS
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-58.0%
Fair Value
$81.23
Current Price
$128.58
$47.35 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 194.1% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
4.5% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. Revenue growth of 11.2% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PACS
The primary concerns for PACS are P/E Ratio, Profit Margin, Altman Z-Score. Debt-to-equity of 3.38 is elevated, increasing financial risk. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.21 — expect wider price swings.
PACS is growing revenue faster at 11.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PACS scores higher overall (60/100 vs 50/100) and 11.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across various sectors through innovative software and hardware systems. The company prioritizes research and development to leverage emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic collaborations and a solid market presence, PACS Group is well-positioned for sustainable growth, making it an attractive investment proposition for institutional investors seeking to participate in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?